ARTEMISMED
Artemis Medicare Services Ltd.
Each stock's 10,000-path forecast, rendered as light.
Artemis Medicare Services Ltd. (ARTEMISMED) Stock Analysis & Case Study
Is ARTEMISMED a good buy? The data-driven verdict.
Artemis Medicare Services Ltd. (ARTEMISMED) trades at ₹316,on the numbers it tread carefully, a Downstox Snapshot Score of 41/100.
On the numbers, Artemis Medicare Services Ltd. (ARTEMISMED) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 43.2× earnings, ROE of 12.0%, a 57% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
ARTEMISMED fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How ARTEMISMED ranks against the 2,373 companies in our screener
- ARTEMISMED's market cap of 5,007 Cr ranks in the 66th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ARTEMISMED's book value of ₹59 ranks in the 38th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ARTEMISMED's promoter holding of 58.4% ranks in the 48th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ARTEMISMED's 3-year profit (PAT) growth of 41.0% ranks in the 79th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ARTEMISMED's 3-year revenue growth of 14.0% ranks in the 60th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ARTEMISMED's debt-to-equity ratio of 0.28x is lower than 54% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is ARTEMISMED overvalued? ARTEMISMED P/E vs peers
ARTEMISMED trades at 43.2× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
ARTEMISMED share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 6.3y of ARTEMISMED history (42%/yr drift, 39%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ARTEMISMED 2027 | ₹205 | ₹339 | ₹563 | +7% |
| ARTEMISMED 2028 | ₹177 | ₹364 | ₹748 | +15% |
| ARTEMISMED 2029 | ₹161 | ₹390 | ₹948 | +23% |
| ARTEMISMED 2030 | ₹150 | ₹419 | ₹1,169 | +32% |
| ARTEMISMED 2031 | ₹143 | ₹449 | ₹1,410 | +42% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ARTEMISMED goes up, or doubles?
The bull case for ARTEMISMED
- ARTEMISMED's return on equity of 12.0% ranks in the 59th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹948.
The bear case & risks
- ARTEMISMED's P/E of 43.2x is lower than 31% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹161.
ARTEMISMED volatility & expected range, how bumpy is the ride?
Over the last 6.3 years ARTEMISMED compounded at 42%/year with annualized volatility of 39%. That volatility implies a 1-year 80% range of ₹205-₹563, the honest backbone behind any single price target.
ARTEMISMED price forecast, the full 60-month probability fan
ARTEMISMED price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ARTEMISMED hits common targets within the simulated horizon?
Full multi-horizon detail on the ARTEMISMED price target & forecast page.
ARTEMISMED Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. ARTEMISMED scores 6/8, mixed financial health.
ARTEMISMED MTF margin & leverage across 9 brokers
Margin Trading Facility lets you buy ARTEMISMED with part of the capital. Lower margin % = higher leverage. Rates compared across 9 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 33.09% | 3.0× |
| Groww | 33.11% | 3.0× |
| Dhan | 35.00% | 2.9× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 41.11% | 2.4× |
| PocketfulCHEAPEST | 32.83% | 3.0× |
| Anand Rathi | 33.09% | 3.0× |
| Share India | 32.85% | 3.0× |
Compare every broker on the ARTEMISMED MTF page.
About Artemis Medicare Services Ltd.: sector, index & market-cap context
Artemis Medicare Services Ltd. (ARTEMISMED) is a small-cap NSE-listed company, with a market capitalisation of ₹5,007 Cr. See more stocks on our screener.
How the ARTEMISMED Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Artemis Medicare Services Ltd.'s public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ARTEMISMED analysis, FAQs
Is Artemis Medicare Services Ltd. (ARTEMISMED) a good buy?
On the numbers, Artemis Medicare Services Ltd. (ARTEMISMED) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 43.2× earnings, ROE of 12.0%, a 57% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ARTEMISMED overvalued or undervalued?
ARTEMISMED trades at 43.2× earnings, expensive versus the ~22× long-run Nifty average.
What is the ARTEMISMED share price target for 2031?
ARTEMISMED's probability-weighted 2031 median target is ₹449, with an 80% range of ₹143-₹1,410 (10,000-path Monte-Carlo).
What is the probability ARTEMISMED doubles in 5 years?
The modelled probability of ARTEMISMED reaching ₹633 (2×) within 5 years is 35%.
What is the bull case for ARTEMISMED?
ARTEMISMED's return on equity of 12.0% ranks in the 59th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in ARTEMISMED?
ARTEMISMED's P/E of 43.2x is lower than 31% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.